ZELTIQ Aesthetics, Inc. To Present At The Canaccord Genuity 32nd Annual Growth Conference

PLEASANTON, Calif., Aug. 8, 2012 (GLOBE NEWSWIRE) -- ZELTIQ® Aesthetics, Inc. (Nasdaq:ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that Mark Foley, Interim President and Chief Executive Officer, is scheduled to present at the Canaccord Genuity 32 nd Annual Growth Conference in Boston, MA.
Event: Canaccord Genuity 32nd Annual Growth Conference
Date: Wednesday, August 15, 2012
Time: 11:00 a.m. PT/ 2:00 p.m. ET

An audio webcast of the Company's presentation will be available by visiting the investor relations section of ZELTIQ's website at www.coolsculpting.com. A replay of the presentation will be available for 30 days.

About ZELTIQ

ZELTIQ® Aesthetics, Inc. (Nasdaq:ZLTQ) is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise. 
CONTACT: Mark Foley         ZELTIQ Aesthetics, Inc.         Interim President, CEO and CFO         925-474-2500                  Nick Laudico / Amy Glynn         The Ruth Group         646-536-7030 / 7023         nlaudico@theruthgroup.com         aglynn@theruthgroup.com

If you liked this article you might like

2 Small Biotechs Under $5 May Be Bargains

Small-Cap Turnaround Stories

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value